Home1JAZZ • BIT
add
Jazz Pharmaceuticals PLC
Previous close
€95.84
Year range
€87.10 - €105.95
Market cap
6.87B USD
Avg Volume
1.00
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Market news
Financials
Income Statement
Revenue
Net income
| (USD) | Jun 2025info | Y/Y change |
|---|---|---|
Revenue | 1.05B | 2.14% |
Operating expense | 710.47M | -0.56% |
Net income | -718.47M | -526.22% |
Net profit margin | -68.71 | -517.44% |
Earnings per share | -8.25 | -255.66% |
EBITDA | 392.98M | 8.41% |
Effective tax rate | 2.33% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Jun 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 1.67B | -15.70% |
Total assets | 10.94B | -3.68% |
Total liabilities | 7.24B | -4.76% |
Total equity | 3.71B | — |
Shares outstanding | 60.66M | — |
Price to book | 1.57 | — |
Return on assets | 4.87% | — |
Return on capital | 5.84% | — |
Cash Flow
Net change in cash
| (USD) | Jun 2025info | Y/Y change |
|---|---|---|
Net income | -718.47M | -526.22% |
Cash from operations | 88.86M | -73.18% |
Cash from investing | -641.02M | -149.34% |
Cash from financing | -124.52M | 22.70% |
Net change in cash | -672.07M | -667.35% |
Free cash flow | 46.83M | -84.01% |
About
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States. One of the company's considerable products is the United States Food and Drug Administration approved drug Xyrem, the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid. In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness in narcolepsy as well as obstructive sleep apnea. In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals.
In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use.
The company is also a member of the Pharmaceutical Research and Manufacturers of America. Wikipedia
Founded
2003
Website
Employees
2,800
